NCT02050334View on ClinicalTrials.gov

CC100: Safety and Tolerability of Single Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

February 28, 2015

Conditions
Healthy
Interventions
DRUG

CC100

CC100 reconstituted in diluent

DRUG

Placebo

Diluent. Amount to match CC100 dose.

Trial Locations (1)

46202

IU Health Neuroscience Center, Indianapolis

All Listed Sponsors
lead

Chemigen, LLC

INDUSTRY

NCT02050334 - CC100: Safety and Tolerability of Single Doses | Biotech Hunter | Biotech Hunter